Roche’s Tecentriq Gets Another Indication In India But Pricing Hurts
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.
You may also be interested in...
Merck has launched Keytruda at an “India-specific” price but some experts say that the immuno-oncology therapy will likely still be beyond the reach of a majority of patients. Merck though also expects to offer a patient access program for those who can’t afford the therapy.
Scrip traces some of the prominent changes in the corner office at front-line, family-owned Indian firms Cipla and Dr Reddy’s in the decade gone by.
Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.